Apogee Therapeutics, Inc.
APGE
Kedudukan dalam Saham
#2365
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Harga Saham
$135.07
Disegerakkan terakhir: 2026-09-04
Modal Pasaran
$8.36B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
137.21%
Negara
US
Perdagangan Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
Sejarah pecahan saham untuk Apogee Therapeutics, Inc. (APGE)
Saham Apogee Therapeutics, Inc. (simbol: APGE) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham APGE yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham APGE.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham APGE yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham APGE.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
